Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data VivoSim Labs, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
4.23
4.6
3.09
2.2
0
1.5
0.37
0.11
0.14
0.13
Cost of revenue
0.96
1
0.5
0.3
0
0.01
0
Gross profit
3.27
3.6
2.59
1.9
0
0.14
0.13
Research and development
19.5
18
14.8
5.28
1.1
3.32
8.89
5.5
5.03
4.19
Selling, general and administrative
22.3
20.9
15.1
18.1
15.7
9.66
9.22
9.7
7.73
7.43
Operating income
-38.6
-35.3
-27.3
-21.5
-16.8
-11.5
-17.7
-15.1
-12.6
-11.5
Interest expense
0
0.01
0.01
Interest income
0.2
0.48
0.71
0.59
0.02
0.01
0.45
0.41
0.14
0.27
Other non-operating income
0.15
0.47
0.64
2.77
0
0.03
0.47
0.42
10.1
-2.35
Pre-tax income
-2.49
-13.8
Income tax
0.02
0
0
0
0
0
0
0
0
0
Net income
-38.4
-34.8
-26.6
-18.7
-16.8
-11.4
-17.3
-14.7
-2.49
-13.8
EBITDA
-37.4
-34
-26.3
-20.3
-16.8
-11.3
-17.4
-14.8
-12.4
-11.3
EPS, basic
-93.84
-77.00
-55.34
-33.69
-29.36
-15.88
-23.82
-19.25
-1.70
-5.35
EPS, diluted
-93.84
-77.00
-55.34
-33.69
-29.36
-15.88
-23.82
-19.25
-1.70
-5.35
Shares, basic (weighted)
0.41
0.45
0.48
0.54
0.57
0.72
0.72
0.76
1.46
2.59
Shares, diluted (weighted)
0.41
0.45
0.48
0.54
0.57
0.72
0.72
0.76
1.46
2.59
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
62.8
43.7
36.5
27.4
37.4
28.7
15.3
2.9
11.3
5.02
Short-term investments
0
Receivables
0.65
0.88
0.5
0.11
0
0
0.15
0.03
0.03
0.03
Inventory
0.55
0.84
0.49
0
0
0.3
0
Other current assets
1.14
1.16
1.05
0.85
1.03
0.86
0.07
0
0.01
0
Total current assets
65.1
46.8
38.6
28.3
38.4
29.5
17
3.94
12.1
6.63
Property, plant and equipment
3.84
2.79
1.83
0
0.38
0.66
0.9
0.67
0.42
0.21
Lease right-of-use assets
0
0
2.15
1.71
1.3
0.87
0.41
Other non-current assets
0.12
0.15
0.14
0.12
1.03
Total assets
69.2
49.8
40.6
28.4
39.9
33.3
20.3
6.35
14.7
7.39
Accounts payable
1.17
0.46
0.63
0.72
0.28
0.42
0.33
0.63
1.64
1.02
Accrued liabilities
4.1
3.34
2.55
1.09
0.44
0.49
2.85
0.73
1.23
0.98
Deferred revenue
0.58
0.67
0.53
0
Total current liabilities
6.01
4.66
3.74
1.81
0.72
1.38
3.67
1.86
3.74
2.79
Lease liabilities
0
0
1.7
1.31
0.89
0.42
0
Total liabilities
6.82
5.24
4.33
1.81
0.72
3.09
4.98
2.75
4.16
8.49
Paid-in capital
262
279
297
306
335
338
340
343
353
355
Retained earnings
-199
-234
-261
-279
-296
-308
-325
-340
-342
-356
Treasury stock
0
-0
-0
-0
-0
-0
0
Other comprehensive income
-0.01
0
0
0
0
Shareholders' equity
62.4
44.6
36.3
26.6
39.2
30.2
15.3
3.6
10.5
-1.1
Total equity
62.4
44.6
36.3
26.6
39.2
30.2
15.3
3.6
10.5
-1.1
Total liabilities and equity
69.2
49.8
40.6
28.4
39.9
33.3
20.3
6.35
14.7
7.39
Shares outstanding
0.43
0.46
0.52
0.54
0.72
0.72
0.72
0.84
1.9
2.89
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-38.4
-34.8
-26.6
-18.7
-16.8
-11.4
-17.3
-14.7
-2.49
-13.8
Depreciation and amortization
1.15
1.27
0.98
1.14
0.04
0.14
0.29
0.28
0.27
0.22
Stock-based compensation
7.39
6.9
5.19
4.11
5.56
2.26
2.38
1.51
0.53
0.3
Change in receivables
-0.39
-0.24
0.38
0.39
0.11
0
-0.15
0.12
0
-0
Change in inventory
-0.22
-0.29
0.35
0.28
0
0
-0.3
-0.5
0
Change in payables
0.38
-0.71
0.16
0.09
-0.44
0.13
-0.15
0.3
1.02
-0.62
Cash from operations
-29.2
-28.9
-20.4
-14.9
-13.3
-8.45
-12.4
-14.7
-9.46
-10.8
Capital expenditures
-1.35
-0.23
-0.08
0
-0.41
-0.41
-0.4
-0.04
-0.01
0
Cash from investing
-1.39
-0.29
-0.08
0.75
-0.39
-0.41
-0.97
0.82
9.03
0.09
Stock issued
0.58
9.38
13.3
5
23.8
0.25
0
1.44
8.85
4.81
Share buybacks
0
-0
0
Cash from financing
31.2
10.1
13.2
4.94
23.8
0.21
0
1.44
8.85
4.45
Exchange rate effect
-0.01
0.01
Net change in cash
0.66
-19
-7.3
-9.2
10.1
-8.66
-13.4
-12.4
8.41
-6.29
Free cash flow
-30.5
-29.1
-20.5
-14.9
-13.7
-8.86
-12.8
-14.7
-9.47
-10.8
Interest paid
0
0
0.01
0.01
Income taxes paid
0.02
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.15 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-10,117.0%
Operating income / revenue.
EBITDA margin
-9,944.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-11,016.0%
Net income / revenue.
FCF margin
-9,038.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-9,018.0%
Cash from operations / revenue.
Return on assets (ROA)
-320.7%
Net income / average total assets.
R&D / revenue
3,857.0%
Research and development expense / revenue.
SG&A / revenue
6,360.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
282.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
20.5%
Capital expenditures / revenue.
D&A / revenue
173.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-9.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-29.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-5.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-110.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-49.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-28.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
76.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
52.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
35.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.70x
Current assets / current liabilities.
Quick ratio
0.90x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.88x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.02
Revenue / diluted weighted shares.
FCF per share
-$1.93
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.93
Cash from operations / diluted weighted shares.
Book value per share
-$0.73
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
20.5x
Market cap / revenue.
EV/Sales
5.59x
Enterprise value / revenue.
FCF yield
-440.9%
Free cash flow / market cap.
Earnings yield
-537.4%
Net income / market cap (the inverse of P/E).
What was VivoSim Labs, INC.'s revenue in fiscal 2026?
VivoSim Labs, INC. reported revenue of $131.0K for fiscal 2026, 9% lower than the year before.
Was VivoSim Labs, INC. profitable in fiscal 2026?
No. It reported a net loss of $13.8M.
How much free cash flow did VivoSim Labs, INC. generate in fiscal 2026?
Cash from operations of $10.8M minus capital expenditures of $0.0 left free cash flow of -$10.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.